We offer validated IHC assays for established ADC targets,including HER2,cMET,B7H3,TROP2,DLL3,EGFR,and Nectin2. We're also actively developing assays for emerging targets,including B7-H4,HER3,ROR1,CEACAM5,and STEAP1,with additional biomarkers coming soon.
"},{"faq_question":"How,and to what extent,must the ADC target be expressed on cancer cells? ","faq_answer":"Target expression is a prerequisite for ADC efficacy. The required level and pattern of expression can vary significantly depending on the ADC and the mechanism of action. CellCarta supports expression analysis across multiple platforms — including IHC,IF,flow cytometry,and mass spectrometry — to help you determine the threshold and distribution of target expression needed for your program."},{"faq_question":"What assay technologies are available? ","faq_answer":"Our ADC platform spans singleplex and multiplex IHC,multiplex immunofluorescence with up to 40 markers per slide,in-situ hybridization (ISH/RNAscope),and FISH. This multi-modal approach allows us to characterise target expression at the protein,RNA,and genomic level within the same tissue context. "},{"faq_question":"How do you assess ADC killing of target cells? ","faq_answer":"Assessing ADC killing efficiency requires evaluating multiple downstream events:target engagement,internalization,linker cleavage,and cytotoxic payload release. CellCarta uses receptor occupancy (RO) assays and transcriptomic approaches (RNAseq,CITE-seq) to indirectly assess binding efficiency and payload activity across both solid and non-solid tumors."},{"faq_question":"Does ADC have on-target,off-tumor effects? ","faq_answer":"Identifying on-target,off-tumor toxicity early is critical for safe ADC development. Our mIF and mIHC platforms evaluate target expression in normal tissues,while flow cytometry tracks circulating target-expressing cell counts as a surrogate for off-target killing. Bulk RNA sequencing and gene set enrichment analysis (GSEA) further investigate activated toxicity pathways. "}];oxy-supreme-cellcarta-cta-banner-items-data:[{"faq_question":"What ADC biomarkers do you support?","faq_answer":"We offer validated IHC assays for established ADC targets,including HER2,cMET,B7H3,TROP2,DLL3,EGFR,and Nectin2. We're also actively developing assays for emerging targets,including B7-H4,HER3,ROR1,CEACAM5,and STEAP1,with additional biomarkers coming soon.
"},{"faq_question":"How,and to what extent,must the ADC target be expressed on cancer cells? ","faq_answer":"Target expression is a prerequisite for ADC efficacy. The required level and pattern of expression can vary significantly depending on the ADC and the mechanism of action. CellCarta supports expression analysis across multiple platforms — including IHC,IF,flow cytometry,and mass spectrometry — to help you determine the threshold and distribution of target expression needed for your program."},{"faq_question":"What assay technologies are available? ","faq_answer":"Our ADC platform spans singleplex and multiplex IHC,multiplex immunofluorescence with up to 40 markers per slide,in-situ hybridization (ISH/RNAscope),and FISH. This multi-modal approach allows us to characterise target expression at the protein,RNA,and genomic level within the same tissue context. "},{"faq_question":"How do you assess ADC killing of target cells? ","faq_answer":"Assessing ADC killing efficiency requires evaluating multiple downstream events:target engagement,internalization,linker cleavage,and cytotoxic payload release. CellCarta uses receptor occupancy (RO) assays and transcriptomic approaches (RNAseq,CITE-seq) to indirectly assess binding efficiency and payload activity across both solid and non-solid tumors."},{"faq_question":"Does ADC have on-target,off-tumor effects? ","faq_answer":"Identifying on-target,off-tumor toxicity early is critical for safe ADC development. Our mIF and mIHC platforms evaluate target expression in normal tissues,while flow cytometry tracks circulating target-expressing cell counts as a surrogate for off-target killing. Bulk RNA sequencing and gene set enrichment analysis (GSEA) further investigate activated toxicity pathways. "}]}#-supreme-cellcarta-differentiators-47-615{items-data:[{"text":"Multi-Omic Integration"},{"text":"Clinical Support "},{"text":"Global Execution "},{"text":"Custom Assay Design "},{"text":"Biomarker Expertise "}]}#-supreme-cellcarta-faq-13-144{items-data:[{"faq_question":"What are targeted protein degraders? ","faq_answer":"Targeted protein degraders are a class of therapeutic modalities designed to degrade disease-associated proteins within cells,including proteins that are considered undruggable. The field of TPDs has grown rapidly,with developers needing specialized biomarker capabilities to monitor target protein degradation,assess potency,and understand resistance mechanisms throughout clinical development.
"},{"faq_question":"How does CellCarta assess TPD potency? ","faq_answer":"CellCarta uses a multi-omic approach for our protein degrader services. Mass spectrometry measures target protein degradation kinetics,depth,and recovery,and evaluates drug specificity in liquid biopsies and tissues. Flow cytometry tracks target protein degradation and explores drug specificity in cell sub-populations. IHC assays provide spatial target protein degradation information from tissue samples. Together,these tools generate the specific and quantitative data required to optimize dosing schedules and assess translational relevance.
"},{"faq_question":"How does CellCarta support TPD resistance analysis? ","faq_answer":"CellCarta offers a range of protein degrader services to decode complex TPD resistance pathways. The TSO500 next-generation sequencing panel,whole exome sequencing,RNA sequencing,and NanoString are used to identify the genomic and transcriptomic drivers of resistance. These tools,combined with patient monitoring capabilities,support biomarker-led trials and help developers quickly unravel and respond to resistance mechanisms.
"},{"faq_question":"What quality standards do you meet for TPD testing? ","faq_answer":"We align to the highest quality standards for TPD biomarker testing. Our laboratories hold CAP accreditation and CLIA certification,and validation processes are designed to meet the requirements for primary and secondary clinical endpoints. These standards support regulatory submissions across global markets.
"},{"faq_question":"Can CellCarta support patient selection in TPD trials? ","faq_answer":"Yes. CellCarta supports optimal patient selection and monitoring through advanced sequencing tools,histology assays,and companion diagnostic (CDx) knowledge. Non-invasive monitoring of circulating tumor cells is available through RareCyte technology,and cytokine storm monitoring can be incorporated to support safety monitoring. These capabilities are designed to support biomarker-led trials across a range of TPD programs.
"}]}#-supreme-cellcarta-featured-resources-16-144{cards-data:[{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"},{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar-2.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"},{"image_url":"\/wp-content\/uploads\/2026\/05\/webinar-3.jpg","card_type":"Webinar","date":"Feb 12","reading_time":"Reading Time - 5 minutes","title":"Resources Title Goes Here","description":"Lorem ipsum dolor sit amet,consectetuer adipiscing elit. Aenean commodo ligula eget dolor.","url":"#"}]}#-supreme-cellcarta-service-blocks-45-176{blocks-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-18-2-1-1-scaled.jpg","image_alt":"","title":"Biomarker Quantification ","description":"Multiplexed biomarker quantification using LC-MS and immunoassays. ","button_text":"Discover","button_url":"/capabilities/proteomics/biomarker-quantification/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta-799-scaled.jpg","image_alt":"","title":"Sequencing Services","description":"In-depth genomics and transcriptomics data for your translational and clinical applications. ","button_text":"Discover","button_url":"/capabilities/genomics/sequencing-services/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/06/Spatial-biology-platform-178.jpg","image_alt":"","title":"Spatial Biology","description":"Dedicated bioinformatics analysis workflow for deep insight into cell phenotypes and spatial relationships in situ. ","button_text":"Discover","button_url":"/capabilities/histopathology/spatial-biology/","button_target":"_self"}]}#-supreme-cellcarta-tab-content-11-144{tabs-data:[{"tab_title":"Multi-Omic Approach ","content_title":"","content_body":"Our scientists employ a multi-omic approach for TPD assessment,such as:
\nWith access to a vast suite of off-the-shelf (OTS) assays and custom development capabilities,we can provide the optimal panel to measure target engagement,degradation,and pharmacodynamics in any biological matrix.
\nOur deep clinical development expertise,including for IVD and CDx deployment,enables effective patient monitoring,stratification,and can unravel mechanisms of TPD resistance,maximizing your clinical trial’s chance of success.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Assay-Development-3-IMG_2160.jpg","image_alt":""},{"tab_title":"Resistance Insights ","content_title":"","content_body":"Overcoming TPD resistance requires rapid decoding of complex biological mechanisms. CellCarta applies our multi-omics workflow to accurately map resistance pathways and monitor activation,including the TSO500 next-generation sequencing and NanoString platforms.
\nTo support concurrent safety surveillance during treatment,our scientists can monitor TPD-associated effects. This includes cytokine storm detection using MSD® and Olink™PEA.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Resistance-Insights-485.jpg","image_alt":""},{"tab_title":"Track TPD Targets","content_title":"","content_body":"Regardless of which TPD target(s) you’re investigating,including KRAS,BRAF,EGFR,BRD4,and STAT3,our multimodal protein degrader services can support your program. Our available capabilities include RNA sequencing,qPCR,IHC,ISH,and mass spectrometry,covering a vast and continually expanding range of biomarkers.
\nTo quantify and measure target degradation,our team can employ digital pathology software for advanced analysis.
\nFor further information,read our TPD postcard.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Patient-Strategies-250.jpg","image_alt":""},{"tab_title":"Scientific Expertise","content_title":"","content_body":"CellCarta brings deep scientific insight to every stage of your therapeutic development journey. Our multidisciplinary teams of medical doctors,scientists,and specialists provide expert guidance from pre-clinical through late stage studies,combining custom assay design with sample logistics support across our eight globally owned and integrated facilities.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-41-2-scaled.jpg","image_alt":""}]}